Home›Stock Screener›Alivus Life Sciences

Alivus Life Sciences Share Price Today | Stock Price & Alivus Life Sciences Share Screener

ALIVUS Pharmaceuticals
Live Share Price NSE
₹1250.60
▼ -18.40 (-1.45%)
2026-10-23 00:00:00
Live Share Price BSE
₹1247.30
▼ -20.20 (-1.59%)
2026-10-23 00:00:00

As of October 23, 2026, the live Alivus Life Sciences share price (NSE: ALIVUS) is ₹1,250.60 on NSE and ₹1,247.30 on BSE, down 1.45% from the previous close, with shares trading between ₹1,208.10 and ₹1,295.80 in today's trading session, and a 52-week range of ₹860.05–₹1,443.70. Check Alivus Life Sciences 52-week for the annual price range and momentum. Use the Alivus Life Sciences stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Alivus Life Sciences opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹2,664 and net income of ₹603, with EBITDA of ₹885, an operating margin of 31.0% and a profit margin of 22.6%.

Alivus Life Sciences Market Cap ₹15,574.79 Cr.
ALIVUS P/E Ratio (TTM) 26.65
Alivus Life Sciences P/B Ratio 4.82
EPS (TTM) ₹45.99
Dividend Yield 0.38%
Debt to Equity 0.02
ALIVUS 52 Week High ₹1443.70
Alivus Life Sciences 52 Week Low ₹860.05
Operating Margin 31.00%
Profit Margin 22.64%
ALIVUS Revenue (TTM) ₹2,664.00
EBITDA ₹885.00
Net Income ₹603.00
Total Assets ₹3,983.00
Total Equity ₹3,332.00

Alivus Life Sciences Share Price Chart

Track the current stock price of Alivus Life Sciences with an interactive chart. Analyse ALIVUS share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Alivus Life Sciences stock quote in one place.

The quote of ₹1,250.60 sits between the 52-week low of ₹860.05 and the 52-week high of ₹1,443.70, and the latest session moved -1.45% from the previous close.

Alivus Life Sciences Company Profile - Fundamental Screener

Screen Alivus Life Sciences company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for ALIVUS shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE03Q201024.

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals
Sub-Sector Pharmaceuticals
Segment E

Identifiers and Leadership

ISIN INE03Q201024

Alivus Life Sciences Balance Sheet Screener

Screen ALIVUS balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹3,983, up from ₹3,411 in 2025.

Latest statistics put total assets at ₹3,983 and shareholder funds at ₹3,332, with a leverage ratio of 0.02.

Item 2026 2025 2024 2023 2022 2021 2020 2019 2018

Assets

Total Assets 3,983 3,411 2,850 2,702 2,471 1,997 1,726 1,475 0
Current Assets 0 0 0 0 0 0 0 0 0
Fixed Assets 1,038 955 805 781 595 573 546 456 0

Liabilities

Total Liabilities 0 0 0 0 0 0 0 0 0
Current Liabilities 143 124 79 67 33 23 16 7 0
Non-Current Liabilities 0 0 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity 3,332 2,817 2,332 2,138 2,054 753 402 88 -1
Share Capital 25 25 25 25 25 2 2 2 0
Reserves & Surplus 3,308 2,793 2,308 2,114 2,030 751 400 86 -1

Alivus Life Sciences Income Statement Screener - Profit & Revenue Analysis

Screen Alivus Life Sciences income statement and profit fundamentals. Analyze ALIVUS quarterly results. Alivus Life Sciences reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For None-None, revenue was ₹2,664 and net profit was ₹603, equal to earnings per unit of ₹49.10, at an operating margin of 31%.

In that period expenses were ₹1,779, interest cost ₹5 and tax ₹195. The next period listed, 2026-March, shows revenue of ₹2,612 and net profit of ₹565.

Item None-None 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March

Revenue and Expenses

Revenue 2,664 2,612 2,421 2,295 2,190 2,138 1,886 1,549 887 0
Expenses 1,779 1,755 1,704 1,609 1,519 1,507 1,294 1,065 639 0

Operating Costs and Margins

EBITDA 885 858 717 686 671 631 592 484 248 0
Operating Profit % 31.00% 31.00% 29.00% 30.00% 30.00% 29.00% 31.00% 31.00% 28.00% -5.00%
Depreciation 79 75 61 54 42 38 33 29 19 0
Interest 5 5 2 2 1 28 88 34 1 0

Profit and Earnings

Profit Before Tax 801 751 654 631 629 565 471 421 228 0
Tax 195 187 169 160 162 146 119 108 33 0
Net Profit 603 565 486 471 467 419 352 313 196 0
EPS 49.10 45.99 39.63 38.43 38.11 35.63 32.61 29.04 24.64 -7.89

Alivus Life Sciences Cash Flow Screener - Liquidity Fundamentals

Screen ALIVUS cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities generated ₹565, and net cash flow was an outflow of ₹69.

Over the same period, investing activities used ₹570 and financing activities used ₹64.

Item 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March

Cash from Operations and Investing

Operating Activities 565 392 414 306 598 388 195 10 -1
Investing Activities -570 -616 -117 -147 -122 -69 -51 -9 0

Financing and Net Cash

Financing Activities -64 -6 -279 -388 -79 -214 -137 1 1
Net Cash Flow -69 -230 18 -228 397 106 8 2 0

Alivus Life Sciences Shareholding Pattern Screener

See Alivus Life Sciences shareholding pattern with promoter, FII, and DII holdings. Check Alivus Life Sciences promoter holding and ownership changes for ALIVUS on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Mar, promoters held 74.87%, foreign institutions 5.29%, domestic institutions 7.28% and the public 9.87%, spread across 127,969 shareholders.

The shareholder count was 127,969 in 2026-Mar, compared with 125,559 in 2026-Jun.

Item 2026-Mar 2026-Jun 2026-Sept 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar

Promoter Holding

Promoter Holding 74.87% 74.87% 74.85% 74.99% 74.94% 74.91% 74.91% 82.85%

Institutional Investors

FII Holding 5.29% 5.54% 5.93% 6.57% 6.42% 6.84% 5.09% 5.01%
DII Holding 7.28% 7.18% 7.03% 5.19% 5.61% 5.47% 7.12% 1.40%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 9.87% 10.05% 10.11% 10.50% 10.34% 10.14% 10.21% 9.09%
Other Holding 2.69% 2.36% 2.08% 2.74% 2.69% 2.64% 2.67% 1.64%
Shareholder Count 127,969 125,559 122,777 141,977 138,500 135,643 132,748 156,183

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Alivus Life Sciences. Alivus Life Sciences dividend yield can be compared with peers and other stocks in the market.

The latest dividend recorded was ₹5.00 per unit for 2026-March, a yield of 0.39%, compared with ₹5.00 for 2025-March.

Dividends are listed for 10 periods, with the three most recent payouts at ₹5.00, ₹5.00 and ₹22.50 per unit.

Period Dividend Per Share Dividend Yield
2026-March ₹5.00 0.39%
2025-March ₹5.00 0.51%
2024-March ₹22.50 2.08%
2023-March ₹42.00 5.41%
2022-March ₹21.00 5.49%
2021-March ₹0.00 0.00%
2020-March ₹0.00 0.00%
2019-March ₹0.00 0.00%
2018-March ₹0.00 0.00%
2017-March ₹0.00 0.00%

Alivus Life Sciences Stock Index Membership - Nifty & Sensex

See which indices include Alivus Life Sciences stock. Check ALIVUS index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

The company is listed in 10 indices, including BSE 1000.

Among the benchmarks tracked are BSE 1000, BSE INDEX BSE HC, BSE INDEX SMLCAP, NIFTY 500.

Complete Index List

BSE 1000
BSE INDEX BSE HC
BSE INDEX SMLCAP
NIFTY 500
NIFTY MIDSML 400
NIFTY SMLCAP 250
NIFTY TOTAL MKT
NIFTY500 EQUAL WEIGHT
NIFTY500 MULTICAP
NIFTY500 SHARIAH

Alivus Life Sciences Market Events Screener - Corporate Actions

Get Alivus Life Sciences corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Alivus Life Sciences stock events that may affect ALIVUS share price, along with derivatives, futures and options activity and sector gainers.

15 corporate actions are listed, the most recent entry being Annual General Meeting dated September 8, 2026, with a record date of September 8, 2026.

It is followed by Dividend dated September 1, 2026 and Quarterly Result Announcement dated July 30, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-09-08 2026-09-08 Annual General Meeting NA 4.19%
2026-09-01 2026-09-01 Dividend ₹ 5.00 /share 30.06%
2026-07-30 2026-07-30 Quarterly Result Announcement NA -1.64%
2026-05-14 2026-05-14 Quarterly Result Announcement NA -3.80%
2026-01-22 2026-01-22 Quarterly Result Announcement NA -1.90%
2025-11-06 2025-11-06 Quarterly Result Announcement NA -0.03%
2025-09-08 2025-09-08 Annual General Meeting NA -1.06%
2025-09-01 2025-09-01 Dividend ₹ 5.00 /share -19.97%
2025-08-01 2025-08-01 Quarterly Result Announcement NA 0.58%
2025-05-15 2025-05-15 Quarterly Result Announcement NA 5.51%
2025-01-23 2025-01-23 Quarterly Result Announcement NA 5.35%
2024-10-24 2024-10-24 Quarterly Result Announcement NA -8.51%
2024-10-09 2024-10-09 Change Of Name NA 0.00%
2024-09-25 2024-09-25 Annual General Meeting NA 2.88%
2023-10-17 2023-10-17 Dividend ₹ 22.50 /share 6.93%

Alivus Life Sciences Competitors Screener - Peer Stocks Comparison

Screen ALIVUS competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 418,204 34.85 61,674 12.69% 11,565 34.47
Divis Laboratories 241,231 83.68 11,067 13.95% 2,568 45.19
Torrent Pharmaceuticals 173,398 80.45 13,886 20.34% 2,138 32.75
Laurus Labs 111,791 102.03 6,868 22.01% 890 61.47
Zydus Life Science 111,112 24.42 27,658 17.64% 5,026 42.73
Cipla 106,969 31.90 29,045 2.24% 3,870 40.05
Dr Reddys Laboratories 103,709 32.30 35,059 3.90% 4,158 59.92
Aurobindo Pharma 93,292 25.74 34,145 5.56% 3,503 40.47
Mankind Pharma 93,067 45.45 14,636 14.85% 1,938 36.17
Lupin 88,678 16.11 29,039 26.75% 5,356 32.65

Alivus Life Sciences Company Announcements - News & Reports Screener

Screen ALIVUS latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated October 9, 2026.

The next most recent announcements are dated October 7, 2026 and September 16, 2026.

Date Update Actions
2026-10-09 Announcement Under Regulation 30 Of SEBI (LODR) 2015 -
2026-10-07 Announcement Under Regulation 30 Of SEBI (LODR) 2015 - Acquisition. -
2026-09-16 The Company Has Incorporated A Wholly Owned Subsidiary Company In Brazil. -
2026-09-11 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-09-08 Shareholder Meeting / Postal Ballot-Scrutinizers Report -
2026-09-08 Shareholder Meeting / Postal Ballot-Outcome of AGM -
2026-09-07 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-09-05 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-08-25 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-08-18 Announcement under Regulation 30 (LODR)-Press Release / Media Release -
2026-08-18 Announcement under Regulation 30 (LODR)-Acquisition -
2026-08-13 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-08-13 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-08-11 Business Responsibility and Sustainability Reporting (BRSR) -
2026-08-11 Reg. 34 (1) Annual Report. -
2026-08-11 Notice Of 15Th Annual General Meeting Of The Company For FY 2025-26 As Required Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 -
2026-08-07 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-08-07 Announcement under Regulation 30 (LODR)-Earnings Call Transcript -
2026-08-06 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-08-06 Intimation Of Record Date For Dividend -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹1,250.60, within a 52-week range of ₹860.05 to ₹1,443.70. The P/E ratio is 26.65 and the P/B ratio is 4.82, with earnings per unit of ₹45.99. Market capitalisation stands at ₹15,574.79 Cr and the dividend yield is 0.38%. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the NSE and the BSE. Key statistics were last updated on October 25, 2026. This page covers 9 balance sheet periods, 10 income statement periods, 9 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.